Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

Clinical trial NCT05112536 · COMPLETED

Trial details

NCT number: NCT05112536
Sponsor: G1 Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Triple Negative Breast Cancer Breast Cancer

Start date: 2022-03-03
Primary completion: 2022-10-31
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.